View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 20, 2021

Inhibikase doses first subject in Phase Ib Parkinson’s treatment trial

The trial will evaluate the safety, pharmacokinetics and tolerability of IkT-148009 in 24 Parkinson’s patients.

Inhibikase Therapeutics has commenced dosing of the first subject in the Phase Ib clinical trial of its drug, IkT-148009, to treat Parkinson’s disease, a neurodegenerative disorder that is progressive.

IkT-148009 is an inhibitor of Abelson Tyrosine Kinase or c-Abl, a clinically established target that is triggered on affected neurons in the brain and gut internalising plaques of alpha-synuclein.

The randomised, placebo-controlled Phase Ib extension trial will analyse the safety, pharmacokinetics and tolerability of IkT-148009 in Parkinson’s patients assessed over seven to 14 days.

It will have 24 subjects categorised into a 3:1 ratio to receive one of the three escalating doses of IkT-148009.

Inhibikase previously submitted the interim 13-week toxicology study data to the US Food and Drug Administration, which subsequently reviewed and accepted the firm’s plans to dose subjects for three months.

Exploratory goals of the trial will include cognitive and motor function, as well as gut motility and alpha-synuclein aggregate clearance measures in various compartments.

Inhibikase Therapeutics president and CEO Milton Werner said: “This is the first time we will assess our selective c-Abl kinase inhibitor in Parkinson’s patients, which could give us an early look into the potential efficacy of this treatment in slowing or possibly halting disease progression and even partly restoring functional loss in Parkinson’s disease.

“As we look ahead, we anticipate completing this study and advancing into a Phase IIa study in 2022.”

According to data from the Phase I trial in 56 healthy elderly subjects, IkT-148009 attained greater drug exposure between 12.5-100mg without any clinically substantial adverse events reported.

These findings were in line with exposures noted in animal efficacy trials of inherited, as well as sporadic progressive Parkinson’s disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena